Metoprolol Succinate ER Tablet
Description
METROOT-XL 12.5
Metoprolol Succinate Extended Release 12.5 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 12.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
METROOT-XL 12.5 contains Metoprolol Succinate Extended Release 12.5 mg, a long-acting beta-1 selective adrenergic receptor blocker formulated for the effective management of hypertension, angina pectoris, chronic heart failure, post-myocardial infarction care, and long-term cardiovascular protection. The extended-release formulation provides sustained therapeutic activity, ensuring stable blood pressure control, effective heart rate reduction, and continuous cardioprotective benefits.
Metoprolol Succinate is widely prescribed in cardiology and internal medicine for patients with essential hypertension, coronary artery disease, chronic heart failure, arrhythmias, ischemic heart disease, and cardiovascular risk reduction. It helps reduce heart rate, myocardial oxygen demand, cardiac workload, and the risk of recurrent cardiovascular events while improving long-term cardiac function.
METROOT-XL 12.5 is particularly beneficial for patients initiating beta-blocker therapy, elderly patients, individuals requiring low-dose cardiovascular treatment, chronic heart failure initiation therapy, and patients requiring gradual dose titration with long-term cardiovascular protection.
Technical Knowledge of Metoprolol Succinate Extended Release
Metoprolol Succinate selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation ensures gradual drug release over an extended period, maintaining stable plasma concentrations and minimizing peak-trough fluctuations.
This sustained beta-1 blockade reduces myocardial oxygen demand, improves ventricular filling time, decreases arrhythmogenic potential, and provides significant cardiovascular protection in patients with hypertension, coronary artery disease, and heart failure.
Mechanism of Action
Metoprolol Succinate selectively blocks beta-1 adrenergic receptors, reduces heart rate and myocardial contractility, decreases cardiac output, suppresses renin release, lowers myocardial oxygen demand, improves ventricular function, and provides sustained cardiovascular protection.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides sustained blood pressure and heart rate control
Reduces myocardial oxygen demand
Supports long-term cardiovascular protection
Improves heart failure outcomes
Reduces the risk of recurrent cardiovascular events
Suitable for low-dose beta-blocker therapy
Convenient once-daily extended-release dosing
Suitable for long-term cardiovascular management under medical supervision
Clinical Applications
METROOT-XL 12.5 is commonly prescribed for essential hypertension, chronic stable angina, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, supraventricular tachycardia, ischemic heart disease, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Metoprolol Succinate
Metoprolol Succinate Extended Release is an evidence-based long-acting beta-blocker with proven benefits in hypertension, coronary artery disease, and chronic heart failure. Large clinical trials have demonstrated significant reductions in cardiovascular morbidity, mortality, hospitalization for heart failure, and recurrent myocardial infarction. The 12.5 mg extended-release strength is particularly useful for therapy initiation, heart failure titration, elderly patients, and individualized cardiovascular management.
Key Facts
Long-acting beta-1 selective blocker
Metoprolol Succinate Extended Release 12.5 mg for sustained cardiovascular control
Provides blood pressure and heart rate management
Effective in hypertension, angina, and chronic heart failure
Supports long-term cardiovascular risk reduction
Evidence-based beta-blocker therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
METROOT-XL 12.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, heart failure, diabetes, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose METROOT-XL 12.5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
METROOT-XL 12.5 from DIABGLYM combines sustained blood pressure control, effective heart rate management, comprehensive cardiovascular protection, evidence-based beta-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release formulation.
